SOPHiA GENETICS (NASDAQ:SOPH) Hits New 1-Year High – Time to Buy?

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) hit a new 52-week high during trading on Monday . The stock traded as high as $6.00 and last traded at $5.9810, with a volume of 195006 shares traded. The stock had previously closed at $5.75.

Analyst Ratings Changes

Several brokerages recently weighed in on SOPH. BTIG Research reissued a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS has an average rating of “Hold” and an average price target of $7.50.

SOPHiA GENETICS Price Performance

The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $498.22 million, a P/E ratio of -11.38 and a beta of 0.98. The business has a 50 day simple moving average of $5.07 and a 200-day simple moving average of $4.92.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million.

Insider Activity

In other news, CEO Jurgi Camblong sold 43,129 shares of the business’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $4.96, for a total value of $213,919.84. Following the sale, the chief executive officer owned 3,664,440 shares of the company’s stock, valued at approximately $18,175,622.40. The trade was a 1.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $5.51, for a total value of $38,261.44. Following the transaction, the chief technology officer directly owned 197,456 shares in the company, valued at approximately $1,087,982.56. The trade was a 3.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 211,743 shares of company stock valued at $1,043,419. Company insiders own 4.88% of the company’s stock.

Institutional Trading of SOPHiA GENETICS

Hedge funds and other institutional investors have recently made changes to their positions in the business. Perkins Capital Management Inc. bought a new position in shares of SOPHiA GENETICS in the fourth quarter valued at $49,000. Squarepoint Ops LLC acquired a new position in shares of SOPHiA GENETICS in the 3rd quarter worth $49,000. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS during the first quarter worth $50,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at $54,000. Finally, XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at $55,000. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.